Zynex (NASDAQ:ZYXI) Updates Q1 2025 Earnings Guidance

Zynex (NASDAQ:ZYXI) recently revised its earnings guidance for the first quarter of 2025. The company now expects its earnings per share (EPS) to be -0.300, which is notably lower than the consensus estimate of 0.060. In addition, Zynex has provided a revenue forecast of $30.0 million, significantly below the consensus revenue estimate of $53.5 million.

Wall Street Analysts Forecast Growth

In a separate report, HC Wainwright reaffirmed a "buy" rating for Zynex and has set a price target of $17.00 for the company's shares. This analysis indicates that despite the current earnings forecast, analysts remain optimistic about Zynex's future performance.

Zynex Stock Performance

During midday trading on Tuesday, shares of Zynex (NASDAQ:ZYXI) fell by $0.17, reaching a price of $7.00. A total of 119,612 shares changed hands, which is higher than the average trading volume of 111,921 shares. Currently, the company has a market capitalization of approximately $222.92 million, a price-to-earnings (P/E) ratio of 46.67, and a beta of 0.81. Zynex's debt-to-equity ratio stands at 1.66, with a quick ratio of 3.15 and a current ratio of 3.94. The stock has fluctuated between a one-year low of $5.44 and a high of $13.19. Its 50-day and 200-day moving averages are at $7.74 and $8.02, respectively.

Zynex's last quarterly earnings report was released on March 11th, where the company reported an EPS of -$0.02, missing the consensus estimate of $0.09 by $0.11. The net margin for the company was 2.49%, and the return on equity (ROE) was recorded at 13.05%. In the same quarter the previous year, Zynex had reported an EPS of $0.04. Analysts project that for the current fiscal year, Zynex will achieve an EPS of around $0.2.

Insider Buying and Selling

In other news regarding Zynex, Chief Financial Officer Daniel J. Moorhead sold 10,000 shares of the company on March 3rd at an average price of $7.15, totaling $71,500. Following this transaction, the CFO owns 10,050 shares, valued at approximately $71,857.50. This sale represents nearly a 50% reduction in their stock position. The transaction details were disclosed in a filing with the SEC. Over the last quarter, insiders collectively sold 30,000 shares worth around $227,100, and insiders hold about 52.13% of the company's stock.

Zynex Company Profile

Zynex, Inc. is engaged in designing, manufacturing, and marketing medical devices focused on treating chronic and acute pain, as well as muscle activation and rehabilitation through electrical stimulation. The company offers a range of products, including NexWave, a dual channel, multi-modality device for interferential current and neuromuscular electrical stimulation (NMES); NeuroMove, which employs electromyography and electrical stimulation technology; InWave, for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, another NMES offering.

Zynex, Earnings, Guidance